Literature DB >> 10437652

The restoration of the antitumor T cell response from stress-induced suppression using a traditional Chinese herbal medicine Hochu-ekki-to (TJ-41:Bu-Zhong-Yi-Qi-Tang).

T Li1, K Tamada, K Abe, H Tada, Y Onoe, K Tatsugami, M Harada, C Kubo, K Nomoto.   

Abstract

We previously reported that restraint stress impairs the antitumor immune responses through its suppressive effect on the Th1-type cytokine production from CD4+ T cells. In this study, we investigated a potential of Hochu-ekki-to (TJ-41:Bu-Zhong-Yi-Qi-Tang) to restore stress-induced immunosuppression. The oral administration of TJ-41 was able to improve a decreased cellularity in the lymph node and spleen and to improve an inhibition of tumor-specific Th1-type cytokine production, both of which were induced by repeated restraint stress in tumor-bearing mice. The oral administration of TJ-41 also induced a partial recovery of the antitumor cytolytic activity in the stress-burdened tumor-bearing mice. More importantly, the growth of tumors in stress-burdened preimmunized mice was obviously inhibited by TJ-41, and resulted in tumor-free state in 75% of the mice. Regarding the mechanisms by which TJ-41 restored the antitumor responses in stress-burdened mice, we found that the serum levels of corticosterone and interleukin-12 were normalized by TJ-41. In addition, the expression of CD80 and CD86, which both decreased in the stress-burdened mice, was restored to the normal level by TJ-41. Taken together, our results indicate that the oral administration of TJ-41 is able to restore the antitumor T cell responses in stress-burdened tumor-bearing mice by normalizing the serum corticosterone, interleukin-12 and the expression of costimulatory molecules.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10437652     DOI: 10.1016/s0162-3109(99)00034-x

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  8 in total

1.  Clinical immunology and traditional herbal medicines.

Authors:  Susan F Plaeger
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

2.  Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis.

Authors:  Lin Ye; Yongning Jia; K E Ji; Andrew J Sanders; Kan Xue; Jiafu Ji; Malcolm D Mason; Wen G Jiang
Journal:  Oncol Lett       Date:  2015-07-06       Impact factor: 2.967

3.  Preventive effect of a traditional herbal medicine, Hochu-ekki-to, on immunosuppression induced by surgical stress.

Authors:  Motohide Kimura; Tetsuro Sasada; Michiyuki Kanai; Yasuhiro Kawai; Yuka Yoshida; Eriko Hayashi; Shingo Iwata; Arimichi Takabayashi
Journal:  Surg Today       Date:  2008-03-27       Impact factor: 2.549

4.  Kampo Medicines for Mite Antigen-Induced Allergic Dermatitis in NC/Nga Mice.

Authors:  Xiu Kun Gao; Kazutoshi Fuseda; Tomonori Shibata; Hiroyuki Tanaka; Naoki Inagaki; Hiroichi Nagai
Journal:  Evid Based Complement Alternat Med       Date:  2005-03-23       Impact factor: 2.629

5.  Bu-zhong-yi-qi pill alleviate the chemotherapy-related fatigue in 4 T1 murine breast cancer model.

Authors:  Mingzi Ouyang; Yanyan Liu; Wei Tan; Ya Xiao; Keqiang Yu; Xiaomin Sun; Ying Huang; JingRu Cheng; Ren Luo; Xiaoshan Zhao
Journal:  BMC Complement Altern Med       Date:  2014-12-15       Impact factor: 3.659

6.  Developing Phytocompounds from Medicinal Plants as Immunomodulators.

Authors:  Chih-Chun Wen; Hui-Ming Chen; Ning-Sun Yang
Journal:  Adv Bot Res       Date:  2012-06-19       Impact factor: 2.175

7.  Bojungikki-Tang Improves Response to PD-L1 Immunotherapy by Regulating the Tumor Microenvironment in MC38 Tumor-Bearing Mice.

Authors:  Jaemoo Chun; Sang-Min Park; Jin-Mu Yi; In Jin Ha; Han Na Kang; Mi-Kyung Jeong
Journal:  Front Pharmacol       Date:  2022-07-06       Impact factor: 5.988

8.  Changes of peripheral blood lymphocyte subtypes in patients with end stage cancer administered localized radiotherapy and bojungikki-tang.

Authors:  A-Jin Lee; Ho Jun Lee; Jong-Dae Kim; Hyun-Jung Jung; Sung Hwa Bae; Hun Mo Ryoo; Sang-Gyung Kim
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-20       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.